Adds a digital support tool to obesity medication in teenagers
Tests a digital support tool with obesity medication in teenagers with obesity.
Plain-language title generated from the registry record
Registry title: The Evira Study: Additional Support During Obesity Treatment
Key facts
- Where
- Linköping, Sollefteå, and Ystad, SwedenSee the 3 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 12 and 17 years old?
Source: NCT06836284, who can take part
Where in Sweden
- HKH Crown Princess Victoria's Childrens and youth Hospital LinköpingLinköping, SwedenTaking people
- Länsverksamhet Barn- och ungdomsmedicin SollefteåSollefteå, SwedenTaking people
- Ystad lasarett, Barn och ungdomsmedicinmottagningenYstad, SwedenTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Karolinska Institutet
- Trial code
- NCT06836284
- Record updated
- 10 September 2026
- Original description
The goal of this clinical trial is to evaluate the effect of adding a digi-physical treatment tool as a complement to the local treatment with obesity medication in adolescents with obesity. The main question it aims to answer is:Read full original descriptionShow less
Evaluation of a Digital Treatment Tool in Combination With Obesity Medications
The goal of this clinical trial is to evaluate the effect of adding a digi-physical treatment tool as a complement to the local treatment with obesity medication in adolescents with obesity. The main question it aims to answer is:
- Can a combination of a digi-physical treatment tool and obesity medication improve treatment outcomes for patients with obesity compared to patients treated with obesity medications alone?
This is a randomized controlled two-arm multicenter study where participants will be randomized to the intervention group (digi-physical treatment+medication) or control group (medication only). Participants will be followed for six months.
Inclusion: Patients offered liraglutide or semaglutide in accordance with the clinic's routines; Aged 12-17 years at the time of inclusion; The family agrees to participate in a clinical study.
Exclusion: Eating disorder requiring treatment within the last six months before inclusion or observed during screening prior to inclusion; Endocrine disorders other than well-controlled hypothyroidism; Severe neuropsychiatric disorders that may affect adherence to the study; Somatic conditions that may complicate the evaluation of treatment outcomes, such as patients on irregular oral corticosteroid treatment; Hypothalamic or monogenic obesity, and genetic syndromes such as Down syndrome; Patients deemed unsuitable for participation by the responsible physician.